Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN). Journal of Clinical Oncology February 2024;42:121-121

Date

02/01/2024

DOI

10.1200/JCO.2024.42.4_suppl.121

Scopus ID

2-s2.0-105024707064 (requires institutional sign-in at Scopus site)   31 Citations

Author List

Beltran H, Dowlati A, Jain P, Johnson ML, Sanborn RE, Thompson JR, Mamdani H, Schenk EL, Aggarwal RR, Sankar K, Gramza AW, Anand BS, Choudhury NJ

Author

Jonathan R. Thompson MD Associate Professor in the Medicine department at Medical College of Wisconsin